journal article·2026-07-30

Targeted Retention of Cationic Liposomes at the Inflamed Blood–Brain Barrier by Incorporating Mesenchymal Stem Cell Membrane

Juanjuan Zheng, Hui Liu, Yaosheng Li, Yuankai Sun, Zefeng Yang, Xunqi Zhang, Zhiwei Du, Jiahe Wu, Liang Pei, Xiaoyu Qiu, Yu Zhao, Xinchi Jiang, Jianqing Gao

Publisher page

Abstract

ABSTRACT Blood–brain barrier (BBB) disruption is found in many acute and chronic inflammatory encephalopathies. Timely restoration of BBB integrity is essential for controlling disease progression, especially in ischemic stroke. While various brain‐targeting strategies have been developed, achieving precise BBB‐targeting and sustained retention at the BBB to enable faster and more effective repair remains a significant challenge. In this study, a biomimetic strategy is developed to enhance inflamed BBB‐targeting gene delivery using cationic hybrid nanovesicles derived from mesenchymal stem cell (MSC) membranes, named P(ML). The combined contributions of the positive surface charge and the biological targeting capability inherent to MSC membranes enable the precise inflamed BBB‐targeting of P(ML). In vitro and in vivo studies demonstrated that P(ML) efficiently accumulated in ischemic brain regions, and exhibited precise retention at inflamed BBB, rather than a diffuse distribution within the whole brain. Additionally, P(ML) showed efficient nucleic acid delivery capability. When loaded with siRNA targeting p66 Shc , a protein involved in endothelial dysfunction, P(ML) exhibited significant protective effects on the injured BBB in animal models. This biomimetic P(ML) nanocarrier platform represents a promising strategy for inflamed BBB‐targeting gene delivery, offering potential therapeutic applications for ischemic stroke and other BBB‐related disorders.
Source: crossref · Quality: baseline

Research context

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Advanced Drug Delivery and Release Systems School of Pharmacy Zhejiang University Hangzhou Zhejiang People's Republic of China

Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine Westlake University Hangzhou Zhejiang People's Republic of China

Innovation Center of Yangtze River Delta Zhejiang University Jiaxing Zhejiang People's Republic of China

Department of Pharmacy The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang People's Republic of China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities

References (68)

Show source-provided references
1. 10.1146/annurev‐cellbio‐100617‐06260810.1146/annurev‐cellbio‐100617‐062608 ↗
2. 10.1038/s41586‐024‐07314‐210.1038/s41586‐024‐07314‐2 ↗
3. 10.1038/s41392‐023‐01688‐x10.1038/s41392‐023‐01688‐x ↗
4. 10.1152/physrev.00050.201710.1152/physrev.00050.2017 ↗
5. 10.1016/j.bbi.2016.03.01010.1016/j.bbi.2016.03.010 ↗
6. 10.1093/brain/awv20310.1093/brain/awv203 ↗
7. 10.1136/jnnp‐2017‐ABN.10310.1136/jnnp‐2017‐ABN.103 ↗
8. 10.1038/ncomms1193410.1038/ncomms11934 ↗
9. 10.1016/j.neuron.2008.01.00310.1016/j.neuron.2008.01.003 ↗
10. 10.1002/smll.20241040410.1002/smll.202410404 ↗
11. 10.1007/s00330‐017‐5025‐310.1007/s00330‐017‐5025‐3 ↗
12. 10.1038/ncomms1052310.1038/ncomms10523 ↗
13. 10.3390/antiox1312146210.3390/antiox13121462 ↗
14. 10.1016/j.bcp.2024.11618610.1016/j.bcp.2024.116186 ↗
15. 10.1161/STROKEAHA.122.03933710.1161/STROKEAHA.122.039337 ↗
16. 10.1126/science.abn792110.1126/science.abn7921 ↗
17. 10.1038/nm.340710.1038/nm.3407 ↗
18. 10.1038/s41583‐024‐00892‐010.1038/s41583‐024‐00892‐0 ↗
19. 10.1161/STROKEAHA.120.03141010.1161/STROKEAHA.120.031410 ↗
20. 10.1038/cr.2017.6210.1038/cr.2017.62 ↗
21. 10.1161/CIRCRESAHA.119.31588610.1161/CIRCRESAHA.119.315886 ↗
22. 10.1093/eurheartj/ehz71210.1093/eurheartj/ehz712 ↗
23. 10.1007/978-1-4939-9798-5_1410.1007/978-1-4939-9798-5_14 ↗
24. 10.1038/s41570‐025‐00770‐y10.1038/s41570‐025‐00770‐y ↗
25. 10.1016/j.jconrel.2016.06.00110.1016/j.jconrel.2016.06.001 ↗
26. 10.1126/scisignal.aaa258110.1126/scisignal.aaa2581 ↗
27. 10.1161/STROKEAHA.111.63788410.1161/STROKEAHA.111.637884 ↗
28. A Pluripotential Neutrophil‐Mimic Nanovehicle Modulates Immune Microenvironment With Targeted Drug Delivery for Augmented Antitumor Chemotherapy
29. 10.1038/s41571‐022‐00699‐x10.1038/s41571‐022‐00699‐x ↗
30. 10.1016/j.jconrel.2025.11432110.1016/j.jconrel.2025.114321 ↗
31. 10.1002/adfm.20200616910.1002/adfm.202006169 ↗
32. 10.1016/j.nantod.2023.10180010.1016/j.nantod.2023.101800 ↗
33. 10.1038/s41392‐024‐01936‐810.1038/s41392‐024‐01936‐8 ↗
34. 10.1016/j.addr.2022.11461910.1016/j.addr.2022.114619 ↗
35. 10.1016/j.jconrel.2024.06.01710.1016/j.jconrel.2024.06.017 ↗
36. 10.1016/j.redox.2023.10261510.1016/j.redox.2023.102615 ↗
37. 10.1016/j.jconrel.2013.09.01310.1016/j.jconrel.2013.09.013 ↗
38. 10.3390/ijms24171354210.3390/ijms241713542 ↗
39. 10.1016/j.jconrel.2022.09.01210.1016/j.jconrel.2022.09.012 ↗
40. 10.1186/s12916‐024‐03768‐310.1186/s12916‐024‐03768‐3 ↗
41. 10.1038/s41467‐025‐58254‐y10.1038/s41467‐025‐58254‐y ↗
42. 10.1016/j.lfs.2024.12261610.1016/j.lfs.2024.122616 ↗
43. 10.1152/ajpcell.00050.202210.1152/ajpcell.00050.2022 ↗
44. 10.1002/adhm.20230031910.1002/adhm.202300319 ↗
45. 10.1038/s41578‐023‐00552‐210.1038/s41578‐023‐00552‐2 ↗
46. 10.1016/j.actbio.2021.05.01910.1016/j.actbio.2021.05.019 ↗
47. 10.1002/adma.20170675910.1002/adma.201706759 ↗
48. 10.1038/nnano.2012.20710.1038/nnano.2012.207 ↗
49. 10.1021/nn501668a10.1021/nn501668a ↗
50. 10.1038/s41392‐024‐02035‐410.1038/s41392‐024‐02035‐4 ↗
51. 10.1002/EXP.2023014710.1002/EXP.20230147 ↗
52. 10.1126/science.275.5301.81010.1126/science.275.5301.810 ↗
53. 10.1073/pnas.230780012010.1073/pnas.2307800120 ↗
54. 10.1038/s41392‐024‐01755‐x10.1038/s41392‐024‐01755‐x ↗
55. 10.1093/eurheartj/ehv14010.1093/eurheartj/ehv140 ↗
56. 10.1016/j.biomaterials.2014.03.01710.1016/j.biomaterials.2014.03.017 ↗
57. 10.1016/j.apsb.2023.10.01210.1016/j.apsb.2023.10.012 ↗
58. 10.1002/VIW.2024004310.1002/VIW.20240043 ↗
59. 10.1038/s41467‐025‐61688‐z10.1038/s41467‐025‐61688‐z ↗
60. 10.1038/s41467‐024‐53914‐x10.1038/s41467‐024‐53914‐x ↗
61. 10.1038/s41392‐022‐01064‐110.1038/s41392‐022‐01064‐1 ↗
62. 10.1523/JNEUROSCI.0324‐18.201810.1523/JNEUROSCI.0324‐18.2018 ↗
63. 10.1038/s41467‐025‐56720‐110.1038/s41467‐025‐56720‐1 ↗
64. 10.1038/s41467‐024‐52346‐x10.1038/s41467‐024‐52346‐x ↗
65. 10.1038/s41467‐025‐62613‐010.1038/s41467‐025‐62613‐0 ↗
66. 10.1002/adma.20180759110.1002/adma.201807591 ↗
67. 10.1161/01.STR.32.4.100510.1161/01.STR.32.4.1005 ↗
68. 10.1038/s41467‐026‐70340‐310.1038/s41467‐026‐70340‐3 ↗